:1970-2022

Fan Jiang1,2,3, Fang Wang4, Tianyu Zhang1

  • 1Department of Urology, The Eighth Medical Center, Chinese PLA General Hospital, Beijing, China (mainland).

PubMed
概括

移植后恶性瘤 (MKT) 研究已经从了解风险因素发展到个性化治疗,如免疫检查点抑制剂. 最近的研究还关注了COVID-19对移植受体的影响.